GB9507298D0
(en)
*
|
1995-04-07 |
1995-05-31 |
Pharmacia Spa |
Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
|
US6906093B2
(en)
|
1995-06-07 |
2005-06-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
US6316635B1
(en)
|
1995-06-07 |
2001-11-13 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US6147106A
(en)
*
|
1997-08-20 |
2000-11-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
US5880141A
(en)
*
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
US6846839B1
(en)
|
1995-06-07 |
2005-01-25 |
Sugen, Inc. |
Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
|
US7119174B2
(en)
|
1995-12-18 |
2006-10-10 |
Sugen, Inc. |
Diagnosis and treatment of AUR1 and/or AUR2 related disorders
|
US6716575B2
(en)
|
1995-12-18 |
2004-04-06 |
Sugen, Inc. |
Diagnosis and treatment of AUR1 and/or AUR2 related disorders
|
GB9610964D0
(en)
*
|
1996-05-24 |
1996-07-31 |
Pharmacia & Upjohn Spa |
Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors
|
US6696448B2
(en)
|
1996-06-05 |
2004-02-24 |
Sugen, Inc. |
3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
|
GB9611797D0
(en)
*
|
1996-06-06 |
1996-08-07 |
Pharmacia Spa |
Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors
|
EP1247803A3
(de)
*
|
1996-08-23 |
2002-10-16 |
Sugen, Inc. |
Indolinon-Verbindungen und deren Verwendung als Protein- Kinase-Modulatoren
|
AU7622698A
(en)
*
|
1996-12-05 |
1998-06-29 |
Sugen, Inc. |
Use of indolinone compounds as modulators of protein kinases
|
WO1998038984A2
(en)
*
|
1997-03-05 |
1998-09-11 |
Sugen, Inc. |
Formulations for hydrophobic pharmaceutical agents
|
WO1998045708A1
(en)
*
|
1997-04-08 |
1998-10-15 |
Sugen, Inc. |
Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
|
US6818440B2
(en)
|
1997-04-28 |
2004-11-16 |
Sugen, Inc. |
Diagnosis and treatment of alk-7 related disorders
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
US6316429B1
(en)
|
1997-05-07 |
2001-11-13 |
Sugen, Inc. |
Bicyclic protein kinase inhibitors
|
US6486185B1
(en)
|
1997-05-07 |
2002-11-26 |
Sugen, Inc. |
3-heteroarylidene-2-indolinone protein kinase inhibitors
|
JP2002511852A
(ja)
*
|
1997-05-07 |
2002-04-16 |
スージェン・インコーポレーテッド |
蛋白質キナーゼ活性の調節剤としての2−インドリノン誘導体
|
US6228641B1
(en)
|
1997-05-20 |
2001-05-08 |
Sugen, Inc. |
Diagnosis and treatment of PTP04 related disorders
|
US7115710B2
(en)
|
1997-06-11 |
2006-10-03 |
Sugen, Inc. |
Diagnosis and treatment of PTP related disorders
|
US6342593B1
(en)
|
1997-06-11 |
2002-01-29 |
Sugen, Inc. |
Diagnosis and treatment of ALP related disorders
|
US6987113B2
(en)
|
1997-06-11 |
2006-01-17 |
Sugen, Inc. |
Tyrosine kinase inhibitors
|
US6388063B1
(en)
|
1997-06-18 |
2002-05-14 |
Sugen, Inc. |
Diagnosis and treatment of SAD related disorders
|
US6235769B1
(en)
|
1997-07-03 |
2001-05-22 |
Sugen, Inc. |
Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
|
GB9718913D0
(en)
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
PT1017384E
(pt)
|
1997-09-26 |
2005-03-31 |
Zentaris Gmbh |
Compostos com base no azabenzimidazole para modulacao da funcao de uma cinase de proteina serina/treonina
|
US6133305A
(en)
|
1997-09-26 |
2000-10-17 |
Sugen, Inc. |
3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
|
UA71555C2
(en)
|
1997-10-06 |
2004-12-15 |
Zentaris Gmbh |
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
|
AU2237899A
(en)
|
1998-01-21 |
1999-08-09 |
Sugen, Inc. |
Human orthologues of wart
|
US6531502B1
(en)
|
1998-01-21 |
2003-03-11 |
Sugen, Inc. |
3-Methylidenyl-2-indolinone modulators of protein kinase
|
US6514981B1
(en)
|
1998-04-02 |
2003-02-04 |
Sugen, Inc. |
Methods of modulating tyrosine protein kinase function with indolinone compounds
|
EP1073723B1
(de)
|
1998-04-14 |
2005-08-17 |
Sugen, Inc. |
Ste20-verwandte proteinkinasen
|
DE19816624A1
(de)
*
|
1998-04-15 |
1999-10-21 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
AU759226B2
(en)
|
1998-05-29 |
2003-04-10 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
CA2342251A1
(en)
|
1998-08-28 |
2000-03-09 |
Scios Inc. |
Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
|
JP2002523455A
(ja)
*
|
1998-08-31 |
2002-07-30 |
スージェン・インコーポレーテッド |
蛋白質キナーゼ活性の調節剤としての幾何学的に制限された2−インドリノン誘導体
|
SI1115704T1
(en)
|
1998-09-25 |
2003-12-31 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes
|
US6680335B2
(en)
|
1998-09-28 |
2004-01-20 |
Sugen, Inc. |
Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
|
US6153634A
(en)
|
1998-12-17 |
2000-11-28 |
Hoffmann-La Roche Inc. |
4,5-azolo-oxindoles
|
ES2192877T3
(es)
|
1998-12-17 |
2003-10-16 |
Hoffmann La Roche |
4-alquenil (y alquinil) oxindoles como inhibidores de kinasas ciclina-dependientes, en particular cdk2.
|
CN1147486C
(zh)
*
|
1998-12-17 |
2004-04-28 |
霍夫曼-拉罗奇有限公司 |
4-和5-炔基羟吲哚和4-和5-烯基羟吲哚
|
TR200101756T2
(tr)
|
1998-12-17 |
2001-10-22 |
F.Hoffmann-La Roche Ag |
Protein kinaz inhibitörleri olarak 4,5-pirazinoksindoller.
|
KR20010101266A
(ko)
|
1998-12-17 |
2001-11-14 |
프리돌린 클라우스너, 롤란드 비. 보레르 |
Jnk 단백질 키나제의 억제제로서의 4-아릴옥신돌
|
US6861442B1
(en)
|
1998-12-30 |
2005-03-01 |
Sugen, Inc. |
PYK2 and inflammation
|
GB9904933D0
(en)
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Compounds
|
US6492398B1
(en)
|
1999-03-04 |
2002-12-10 |
Smithkline Beechman Corporation |
Thiazoloindolinone compounds
|
US6624171B1
(en)
|
1999-03-04 |
2003-09-23 |
Smithkline Beecham Corporation |
Substituted aza-oxindole derivatives
|
US7064114B2
(en)
|
1999-03-19 |
2006-06-20 |
Parker Hughes Institute |
Gel-microemulsion formulations
|
EP1165513A1
(de)
*
|
1999-03-24 |
2002-01-02 |
Sugen, Inc. |
Indolinon derivate als kinase inhibitoren
|
US6689806B1
(en)
|
1999-03-24 |
2004-02-10 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
US6541477B2
(en)
|
1999-08-27 |
2003-04-01 |
Scios, Inc. |
Inhibitors of p38-a kinase
|
WO2001031005A2
(en)
|
1999-10-22 |
2001-05-03 |
Pharmacia & Upjohn Company |
Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
US6313310B1
(en)
|
1999-12-15 |
2001-11-06 |
Hoffmann-La Roche Inc. |
4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
|
NZ519697A
(en)
|
1999-12-22 |
2004-08-27 |
Sugen Inc |
Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
|
US6620818B1
(en)
|
2000-03-01 |
2003-09-16 |
Smithkline Beecham Corporation |
Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
|
US6734005B2
(en)
|
2000-05-22 |
2004-05-11 |
Pharmacia & Upjohn Company |
Matrix metalloproteinases
|
MY128450A
(en)
|
2000-05-24 |
2007-02-28 |
Upjohn Co |
1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
WO2001094312A2
(en)
|
2000-06-02 |
2001-12-13 |
Sugen, Inc. |
Indolinone derivatives as protein kinase/phosphatase inhibitors
|
WO2002002639A2
(en)
|
2000-07-05 |
2002-01-10 |
Pharmacia & Upjohn Company |
Human ion channels
|
US6504034B2
(en)
|
2001-01-23 |
2003-01-07 |
Hoffmann-La Roche Inc. |
Naphthostyrils
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
PE20030062A1
(es)
|
2001-05-30 |
2003-02-08 |
Sugen Inc |
Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
|
WO2003000251A1
(en)
*
|
2001-06-21 |
2003-01-03 |
Ariad Pharmaceuticals, Inc. |
Novel idolinones and uses thereof
|
DE10134196B4
(de)
*
|
2001-07-13 |
2005-08-18 |
Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt |
Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
US8034831B2
(en)
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
KR20120035234A
(ko)
|
2003-04-11 |
2012-04-13 |
메디뮨 엘엘씨 |
재조합 il?9 항체 및 그의 용도
|
CA2536238C
(en)
|
2003-08-18 |
2015-04-07 |
Medimmune, Inc. |
Humanization of antibodies
|
DK1773816T3
(en)
|
2004-06-24 |
2015-01-26 |
Vertex Pharma |
Modulators of ATP-binding cassette transporters
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
AU2006227377B2
(en)
|
2005-03-18 |
2013-01-31 |
Medimmune, Llc |
Framework-shuffling of antibodies
|
KR20080025174A
(ko)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
응집 및 단편화 프로파일이 최적화된 항체 제제
|
US20090105272A1
(en)
*
|
2005-12-24 |
2009-04-23 |
Grootenhuis Peter D J |
Prodrugs of modulators of ABC transporters
|
JP5409010B2
(ja)
|
2005-12-28 |
2014-02-05 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
N−[2,4−ビス(1,1−ジメチルエチル)−5−ヒドロキシフェニル]−1,4−ジヒドロ−4−オキソキノリン−3−カルボキサミドの固体形態
|
MX2009002151A
(es)
|
2006-08-28 |
2009-07-03 |
Kirin Pharma Kk |
Anticuerpos monoclonales humanos especificos para light humano antagonistas.
|
EP2077859A4
(de)
|
2007-03-30 |
2010-11-24 |
Medimmune Llc |
Antikörper-formulierung
|
IE20070928A1
(en)
*
|
2007-12-21 |
2009-09-30 |
Giuliani Int Ltd |
Multi target ligands
|
NZ624460A
(en)
|
2009-03-20 |
2015-12-24 |
Vertex Pharma |
Process for making modulators of cystic fibrosis transmembrane conductance regulator
|
WO2013033680A1
(en)
|
2011-09-02 |
2013-03-07 |
Lifenet Health |
Bmp peptides & methods of use
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
CN104470518A
(zh)
|
2012-02-27 |
2015-03-25 |
沃泰克斯药物股份有限公司 |
药物组合物及其施用
|
NZ630363A
(en)
|
2012-07-25 |
2018-09-28 |
Celldex Therapeutics Inc |
Anti-kit antibodies and uses thereof
|
SG11201502757QA
(en)
|
2012-10-09 |
2015-05-28 |
Igenica Biotherapeutics Inc |
Anti-c16orf54 antibodies and methods of use thereof
|
US10100123B2
(en)
|
2013-06-06 |
2018-10-16 |
Pierre Fabre Medicament |
Anti-C10orf54 antibodies and uses thereof
|
KR20160054501A
(ko)
|
2013-08-26 |
2016-05-16 |
맵백스 테라퓨틱스, 인코포레이티드 |
시알릴-루이스 a에 대한 사람 항체 코드화 핵산
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
WO2015187811A2
(en)
|
2014-06-04 |
2015-12-10 |
MabVax Therapeutics, Inc. |
Human monoclonal antibodies to ganglioside gd2
|
US20170246259A1
(en)
|
2014-09-10 |
2017-08-31 |
Georgetown University |
Compositions and Methods of Using Interleukin-4 Induced Gene 1 (IL-4I1)
|
CA2963945C
(en)
|
2014-10-07 |
2023-01-10 |
Vertex Pharmaceuticals Incorporated |
Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
|
ES2834739T3
(es)
|
2014-12-11 |
2021-06-18 |
Pf Medicament |
Anticuerpos anti-C10orf54 y utilizaciones de los mismos
|
PL3265123T3
(pl)
|
2015-03-03 |
2023-03-13 |
Kymab Limited |
Przeciwciała, zastosowania i sposoby
|
CN108925136B
(zh)
|
2015-12-02 |
2022-02-01 |
斯特赛恩斯公司 |
特异于糖基化的btla(b和t淋巴细胞衰减因子)的抗体
|
CN114470194A
(zh)
|
2015-12-02 |
2022-05-13 |
斯特库伯株式会社 |
与btn1a1免疫特异性结合的抗体和分子及其治疗用途
|
EP3534947A1
(de)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
|
AU2018277838A1
(en)
|
2017-05-31 |
2019-12-19 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
US20200131266A1
(en)
|
2017-05-31 |
2020-04-30 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
JP2020522562A
(ja)
|
2017-06-06 |
2020-07-30 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法
|
WO2019073069A1
(en)
|
2017-10-13 |
2019-04-18 |
Boehringer Ingelheim International Gmbh |
HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
|
MX2021000786A
(es)
|
2018-07-20 |
2021-06-15 |
Pf Medicament |
Receptor para supresor de ig del dominio v de activación de células t (vista).
|
CN111675647B
(zh)
*
|
2020-06-26 |
2022-03-01 |
深圳技术大学 |
2-吲哚酮类pak1抑制剂及其在抗肿瘤治疗药物中的应用
|